Malignant Gliomas
19
0
1
14
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.8%
3 terminated out of 19 trials
82.4%
-4.2% vs benchmark
0%
0 trials in Phase 3/4
36%
5 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (19)
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
Fluorescence and Glioma Heterogeneity
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
ZD6474 to Treat Advanced Brain Cancer in Patients
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
Sunitinib to Treat Recurrent Brain Cancer
Imaging Study of Glioblastomas Treated With Avastin
Bevacizumab for Recurrent Malignant Glioma
Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas